NeuroNEXT

The AAN is collaborating with the Medical University of South Carolina (MUSC) to offer The TRANSCENDS (Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars) Scholars program. This program is funded by a NINDS R25. The TRANSCENDS program is designed to train promising early-career neurologists to conduct high-quality…

NeuroNEXT was well-represented at the 40th Annual Meeting of the Society for Clinical Trials (SCT) this week. The meeting – hosted in New Orleans, LA, May 19-22, 2019 – featured two invited sessions by NeuroNEXT personnel: One contributed session also featured NeuroNEXT: And one poster session: Thanks to everyone for for promoting the excellent work of the…

NIH is soliciting for Pain Research Centers to join a clinical trial network.  NIH has mounted a major effort to improve pain management as a part of its response to the opioid crisis in America.  One cornerstone of that effort is an phase 2 clinical trial network to test new, non-addictive pain therapies in well-phenotyped…

Dr. Robert Fox, PI of the NN102 SPRINT-MS study was the 2019 recipient of Cleveland Clinic’s Sones Innovation Award for the advances in progressive multiple sclerosis made by the NN102 study. This award recognizes advances in innovation in the service of improved patient care. Congratulations to Dr. Fox and the NN102 SPRINT-MS team!

The dataset from the NN102 SPRINT-MS project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov. 

Applications for the NINDS-funded Clinical Trials Methodology Course (CTMC) 2019 are due February 28, 2019 at midnight. Application forms and additional details are available at http://neurotrials.training. Early applications may be considered for early acceptance. 

The NN104 RHAPSODY primary manuscript has been published in the January 2019 print issue of Annals of Neurology. As the abstract notes, this trial was important for three reasons: Congratulations to Dr. Lyden and the NN104 RHAPSODY team. The success of this academic/industry partnership is another major statement of the many benefits that NeuroNEXT brings to the conduct of high-quality phase II studies in the neurosciences.

NN101 SMA was recently featured in the Cure SMA newsletter, highlighting the recently-published Recruitment & Retention paper. 

Dr. Merit Cudkowicz, Principal Investigator of the NeuroNEXT CCC, was interviewed on CBS News’ 60 Minutes on a feature about NFL star Tim Green coping with ALS. Her appearance begins at the 6:15 mark, and she discusses Mr. Green’s prognosis and treatment. 

The slide presentation from the 2018 NeuroNEXT Annual Meeting in Boston, MA October 18-19 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!